Free Trial
NASDAQ:SLS

SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis

SELLAS Life Sciences Group logo
$1.18
-0.01 (-0.84%)
(As of 10/31/2024 ET)

About SELLAS Life Sciences Group Stock (NASDAQ:SLS)

Key Stats

Today's Range
$1.14
$1.21
50-Day Range
$1.10
$1.35
52-Week Range
$0.50
$1.72
Volume
683,391 shs
Average Volume
1.09 million shs
Market Capitalization
$75.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Consensus Rating
Buy

Company Overview

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

SELLAS Life Sciences Group Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
42nd Percentile Overall Score

SLS MarketRank™: 

SELLAS Life Sciences Group scored higher than 42% of companies evaluated by MarketBeat, and ranked 736th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for SELLAS Life Sciences Group are expected to grow in the coming year, from ($0.55) to ($0.42) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of SELLAS Life Sciences Group is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of SELLAS Life Sciences Group is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about SELLAS Life Sciences Group's valuation and earnings.
  • Percentage of Shares Shorted

    9.45% of the outstanding shares of SELLAS Life Sciences Group have been sold short.
  • Short Interest Ratio / Days to Cover

    SELLAS Life Sciences Group has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in SELLAS Life Sciences Group has recently decreased by 25.67%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    SELLAS Life Sciences Group does not currently pay a dividend.

  • Dividend Growth

    SELLAS Life Sciences Group does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.45% of the outstanding shares of SELLAS Life Sciences Group have been sold short.
  • Short Interest Ratio / Days to Cover

    SELLAS Life Sciences Group has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in SELLAS Life Sciences Group has recently decreased by 25.67%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    SELLAS Life Sciences Group has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for SELLAS Life Sciences Group this week, compared to 2 articles on an average week.
  • Search Interest

    Only 6 people have searched for SLS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, SELLAS Life Sciences Group insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.20% of the stock of SELLAS Life Sciences Group is held by insiders.

  • Percentage Held by Institutions

    Only 17.38% of the stock of SELLAS Life Sciences Group is held by institutions.

  • Read more about SELLAS Life Sciences Group's insider trading history.
Receive SLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter.

SLS Stock News Headlines

Banking failure dead ahead
If you missed it, my emergency election broadcast is now available - but will be removed soon
See More Headlines

SLS Stock Analysis - Frequently Asked Questions

SELLAS Life Sciences Group's stock was trading at $1.06 at the beginning of the year. Since then, SLS stock has increased by 11.3% and is now trading at $1.18.
View the best growth stocks for 2024 here
.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) posted its earnings results on Tuesday, August, 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03.

SELLAS Life Sciences Group shares reverse split on the morning of Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that SELLAS Life Sciences Group investors own include (UNISQ) (UNISQ), Amgen (AMGN), Generex Biotechnology (GNBT), Salesforce (CRM), Bank of America (BAC), Bristol-Myers Squibb (BMY) and AbbVie (ABBV).

Company Calendar

Last Earnings
8/13/2024
Today
10/31/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SLS
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$3.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+154.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-37,340,000.00
Pretax Margin
N/A
Return on Equity
-17,349.61%

Debt

Sales & Book Value

Annual Sales
$1 million
Book Value
($0.25) per share

Miscellaneous

Free Float
63,560,000
Market Cap
$75.91 million
Optionable
Not Optionable
Beta
2.39
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:SLS) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners